Figure 1.
Enrichment approaches for patient selection in clinical trials. Biomarkers can be used to select patients based on risk of disease progression (baseline risk enrichment; green shaded area), based on the drug response before exposure (predictive response enrichment; blue shaded area), or based on the change in a biomarker after short‐term exposure to the drug (dynamic response enrichment; orange shaded area). The ideal biomarker or set of biomarkers would capture the three domains